Looks like Kedrion chose to pass up the option!Looks like Kedrion chose to pass up the option!
I imagine, Given that it is now June 16, and the new job postings published by LMLNL means that Kedrion (who knows this market very well) has decided that the negatives of carrying the costs of taking up the option and the costs of carrying PBI and PBT would not be covered by the small revenue stream from the Ryplazim approval, which after all is only a small indication with a small revenue stream, even with the $30 M kicker from the potential sale of the PRV voucher. Remains to be seen what actuallt happens here and whether either LMNL or Kedrion will issue a PR to clarify the situation.